Candel Therapeutics Inc
CADL
Get informed when a big investor buys or sells
+ FollowMarket Cap$807.44M
Close$
$2.22
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $807.44 Million |
|---|---|
| Enterprise Value | $655.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.72 |
| Beta | -0.47 |
| Outstanding Shares | 74,131,229 |
Return
| Return on Equity | -37.87% |
|---|---|
| Return on Assets | -22.95% |
| Return on Invested Capital | -30.56% |
Valuation & Multiples
| P/E Ratio | -7.82 |
|---|---|
| PEG | -1.1 |
| Price to Sales | - |
| Price to Book Ratio | 11.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.97 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3399▼ 4.00% |
|---|---|
| Total Calls | 309,800▼ 16.65% |
| Total Puts | 105,300▼ 25.42% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 68.64%▼ 1.00% |
|---|---|
| Total Invested | $523.94M▲ 146.07% |
| Investors Holding | 146▲ 28.00% |
ESG Score
No data
About Candel Therapeutics Inc
2,021 employees